Literature DB >> 16469269

Does ACE inhibitor therapy delay onset and progression of cardiac dysfunction in duchenne muscular dystrophy?

Michio Hirano.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16469269     DOI: 10.1007/s11910-996-0007-x

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


× No keyword cloud information.
  5 in total

1.  Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation.

Authors:  Michelle Eagle; Simon V Baudouin; Colin Chandler; David R Giddings; Robert Bullock; Kate Bushby
Journal:  Neuromuscul Disord       Date:  2002-12       Impact factor: 4.296

Review 2.  Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement.

Authors:  Jonathan D Finder; David Birnkrant; John Carl; Harold J Farber; David Gozal; Susan T Iannaccone; Thomas Kovesi; Richard M Kravitz; Howard Panitch; Craig Schramm; Mary Schroth; Girish Sharma; Lisa Sievers; Jean M Silvestri; Laura Sterni
Journal:  Am J Respir Crit Care Med       Date:  2004-08-15       Impact factor: 21.405

3.  The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy.

Authors:  G Nigro; L I Comi; L Politano; R J Bain
Journal:  Int J Cardiol       Date:  1990-03       Impact factor: 4.164

Review 4.  The heart in human dystrophinopathies.

Authors:  Josef Finsterer; Claudia Stöllberger
Journal:  Cardiology       Date:  2003       Impact factor: 1.869

5.  Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.

Authors:  R T Moxley; S Ashwal; S Pandya; A Connolly; J Florence; K Mathews; L Baumbach; C McDonald; M Sussman; C Wade
Journal:  Neurology       Date:  2005-01-11       Impact factor: 9.910

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.